Please upgrade your browser.
Can statin drugs help prevent kidney cancer? This edition also includes a link to videos that will help you to learn how to take your anti-cancer drug, along with information about side effects.
Kidney Cancer Association and Conquer Cancer Foundation work together to promote and sponsor research projects.
A pre-filtered list of abstracts related to renal cell carcinoma (RCC) from the 2013 Annual Meeting of the American Society of Clinical Oncology, held this week in Chicago.
We have launched a patient registry for kidney cancer.
ASONEP is a humanized antibody that binds to and neutralizes sphingosine-1-phosphate (S1P). S1P is a bioactive lipid that has been validated as a drug target in multiple sclerosis and that has been shown to contribute to progression of several cancer types.
Founding registry partners voice strong support for the shared, open-access registry able to collect data on any disease, from rare to common.
Members of the Kidney Cancer Association Nurse Advisory Board discuss targeted therapies and management of side effects.
View expert presentations and download Powerpoint slides from this important kidney cancer meeting held recently in Budapest, Hungary.
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
AVEO Oncology and Astellas Pharma Inc. announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
|Powered by NeonCRM|